The HIV-1 reverse transcriptase mutants G190S and G190A, which confer resistance to non-nucleoside reverse transcriptase inhibitors, demonstrate reductions in RNase H activity and DNA synthesis from tRNA(Lys, 3) that correlate with reductions in rep
about
Structural Maturation of HIV-1 Reverse Transcriptase-A Metamorphic Solution to Genomic InstabilityCommunity HIV-1 drug resistance is associated with transmitted drug resistanceA novel molecular mechanism of dual resistance to nucleoside and nonnucleoside reverse transcriptase inhibitors.The non-nucleoside reverse transcriptase inhibitor efavirenz stimulates replication of human immunodeficiency virus type 1 harboring certain non-nucleoside resistance mutations.Effects of the W153L substitution in HIV reverse transcriptase on viral replication and drug resistance to multiple categories of reverse transcriptase inhibitors.N348I in HIV-1 reverse transcriptase can counteract the nevirapine-mediated bias toward RNase H cleavage during plus-strand initiation.Reduced fitness in cell culture of HIV-1 with nonnucleoside reverse transcriptase inhibitor-resistant mutations correlates with relative levels of reverse transcriptase content and RNase H activity in virions.HIV-1 diversity after a class switch failure.Human immunodeficiency virus type 1 protease inhibitor drug-resistant mutants give discordant results when compared in single-cycle and multiple-cycle fitness assays.Select resistance-associated mutations in blood are associated with lower CSF viral loads and better neuropsychological performance.Evaluation of a multiple-cycle, recombinant virus, growth competition assay that uses flow cytometry to measure replication efficiency of human immunodeficiency virus type 1 in cell culture.The development of drug resistance mutations K103N Y181C and G190A in long term Nevirapine-containing antiviral therapy.In vitro resistance profile of the candidate HIV-1 microbicide drug dapivirineRelative replication fitness of efavirenz-resistant mutants of HIV-1: correlation with frequency during clinical therapy and evidence of compensation for the reduced fitness of K103N + L100I by the nucleoside resistance mutation L74V.Immune-mediated attenuation of HIV-1A sensitive real-time PCR based assay to estimate the impact of amino acid substitutions on the competitive replication fitness of human immunodeficiency virus type 1 in cell cultureClinical significance of human immunodeficiency virus type 1 replication fitness.The connection domain mutation N348I in HIV-1 reverse transcriptase enhances resistance to etravirine and rilpivirine but restricts the emergence of the E138K resistance mutation by diminishing viral replication capacity.Clinical significance of HIV reverse-transcriptase inhibitor-resistance mutations.Nonnucleoside reverse transcriptase inhibitor-resistant HIV is stimulated by efavirenz during early stages of infectionL74V increases the reverse transcriptase content of HIV-1 virions with non-nucleoside reverse transcriptase drug-resistant mutations L100I+K103N and K101E+G190S, which results in increased fitness.The M230L nonnucleoside reverse transcriptase inhibitor resistance mutation in HIV-1 reverse transcriptase impairs enzymatic function and viral replicative capacity.Pairwise growth competition assay for determining the replication fitness of human immunodeficiency viruses.Reverse transcriptase backbone can alter the polymerization and RNase activities of non-nucleoside reverse transcriptase mutants K101E+G190S.Factors associated with the emergence of K65R in patients with HIV-1 infection treated with combination antiretroviral therapy containing tenofovir.
P2860
Q28074527-BA012905-F31D-43C9-B536-C0409BA4CD23Q33748960-914C56E6-D9A5-44FD-A4F7-A4CD2A570D5BQ33826904-49952249-D88A-4AE1-8208-05CEC903E8AEQ33872810-735701D8-FB51-4A03-BBD4-737AB7E9B8CAQ34058254-C3CE779F-A08A-46DC-832A-B2D4E833225CQ34094395-7FC26EDA-7EA3-4155-8139-B3DCADBE32DCQ34120147-64CDAE24-D3DD-4748-B41C-0A44CDCF3B23Q34399268-A6C5BBBD-945A-4919-9B9C-7D74D4F91F20Q34489422-B20121F9-13B8-49FA-B2AF-F0B3E42AE734Q34615228-F5610507-8ABA-48D3-A70C-D89B3061843CQ34719435-BA3161B3-2920-4182-AC66-4A80D72DC957Q35552675-A8F9FC8C-5AE5-487F-8B5F-AE34E0DC19F3Q35689311-999553D5-73EA-4687-8E61-47095DC982DAQ35794287-F0E27C2D-85E5-4EE8-95A1-65A4B7B41AA3Q35798108-B075CA69-327B-454E-80A9-06C76E3AEB4AQ36718337-E9F8CDDC-EB5C-4E05-930E-890CC5771F85Q36969857-1832360D-CFC8-4ACA-97C4-1457F8AD32F6Q37547275-CDB5C9F9-83BE-4004-BA97-605EC2A4D835Q37859395-3F75A942-8A27-45CF-8BB9-73E40FAC0030Q38632038-38904309-A6E9-4DA1-8B70-9DCBC72877EFQ39174700-795A76A1-2A20-41FF-826D-ED9DD2B631ADQ39724626-D23876D3-E28F-40AC-B680-D15C01F87CBFQ41213664-BA26344D-5B2F-487E-BF05-EF8AA2032628Q42159090-EB5E9885-DE07-43CA-88DF-CAC4A48D23E1Q44741225-B1F25658-479C-4F7A-8A70-75D82FBF7ADC
P2860
The HIV-1 reverse transcriptase mutants G190S and G190A, which confer resistance to non-nucleoside reverse transcriptase inhibitors, demonstrate reductions in RNase H activity and DNA synthesis from tRNA(Lys, 3) that correlate with reductions in rep
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
The HIV-1 reverse transcriptas ...... rrelate with reductions in rep
@ast
The HIV-1 reverse transcriptas ...... rrelate with reductions in rep
@en
type
label
The HIV-1 reverse transcriptas ...... rrelate with reductions in rep
@ast
The HIV-1 reverse transcriptas ...... rrelate with reductions in rep
@en
prefLabel
The HIV-1 reverse transcriptas ...... rrelate with reductions in rep
@ast
The HIV-1 reverse transcriptas ...... rrelate with reductions in rep
@en
P2093
P2860
P1433
P1476
The HIV-1 reverse transcriptas ...... ions in replication efficiency
@en
P2093
L M Demeter
R A Bambara
R A Domaoal
P2860
P304
P356
10.1016/J.VIROL.2006.01.014
P407
P50
P577
2006-02-28T00:00:00Z